Research programme: superoxide dismutase mimetics - Galera Therapeutics
Alternative Names: Dismutase mimetics - Galera TherapeuticsLatest Information Update: 22 Feb 2023
At a glance
- Originator Galera Therapeutics
- Class Small molecules
- Mechanism of Action Antioxidants; Superoxide dismutase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Fibrosis; Stomatitis
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Cancer in USA (unspecified route) (Galera therapeutics pipline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Fibrosis in USA (unspecified route) (Galera therapeutics pipline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Stomatitis (Chemotherapy-induced) in USA (unspecified route) (Galera therapeutics pipline, February 2023)